Hims & Hers Stock Declines 50% in 2026
Shares of telehealth company Hims & Hers have dropped 50% since the beginning of 2026. The significant decline highlights the volatility within high-growth sectors and the market's reaction to the company's forward-looking projections.
- The recent stock collapse was triggered by a series of events in February 2026, including an FDA warning against the company's new compounded weight-loss pill, calling it an "illegal copycat," and a subsequent patent infringement lawsuit from Novo Nordisk. - This regulatory and legal pressure directly challenged the company's core growth strategy, which had become heavily reliant on its compounded GLP-1 weight loss offerings to drive subscription growth. - Prior to the sharp 2026 decline, the stock had already experienced significant volatility, peaking at over $73 in February 2025 before trending downward and closing 2025 at $32.81. - In late 2025, the company had lowered its full-year revenue guidance and adjusted its expected EBITDA margin, signaling to investors a potential slowdown. - The company's upcoming fourth-quarter and full-year 2025 financial results, scheduled for announcement on February 23, 2026, will provide crucial insight into performance leading up to the stock's recent collapse. - In response to the setbacks in the weight-loss market, CEO Andrew Dudum has emphasized diversification into other health areas, including menopause care, low testosterone treatment, and lab testing, while maintaining an ambitious 2030 revenue target of $6.5 billion. - Despite the stock's dramatic fall, the consensus rating among 17 Wall Street analysts is a "Hold," with price targets showing a very wide range, from a low of $16.50 to a high of $68.00, reflecting deep uncertainty about the company's future. - The broader telehealth industry continues to face an evolving regulatory landscape in 2026, which remains a defining factor for all companies in the sector.
